23 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
to execute on our mission of extending the lives of cancer patients.”
FOURTH QUARTER and FULL YEAR 2023 FINANCIAL RESULTS
Net revenue was $91.5 million
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
27 Oct 23
Regulation FD Disclosure
4:19pm
for the prevention and treatment of COVID-19.
With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs”, Junshi
8-K
EX-99.1
iscl lfcankxf89gl9
8 Nov 21
Coherus BioSciences Reports Third Quarter 2021 Results
4:06pm
8-K
EX-99.1
5k4h51nw35p6
13 Oct 21
Departure of Directors or Certain Officers
5:01pm
8-K
EX-99.1
wn9r4b3x
29 Sep 21
Departure of Directors or Certain Officers
5:07pm
8-K
EX-99.1
icmoezti7
5 Aug 21
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:06pm
8-K
EX-99.1
xqnrv9b2f1ix
6 May 21
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:24pm
8-K
EX-99.1
2dis85a8xpjkezr3c0
24 Feb 21
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
4:05pm
8-K
EX-99.1
gfp4nfyo
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
8-K
EX-99.2
jz433d t4rrw
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
8-K
EX-99.1
61b1jt0sk 2ux
5 Nov 20
Coherus BioSciences Reports Third Quarter 2020 Financial Results
4:07pm